#GANX hashtag - Bluesky

Gain Therapeutics Presents Additional Clinical and Biomarker Data from Phase 1b Clinical Study of GT-02287 and Preclinical Data from Novel Chemical Series at AD/PD 2026 Gain Therapeutics (NASDAQ: GANX) presented Phase 1b clinical and preclinical data at AD/PD 2026 supporting continued development of GT-02287 and a new chemical series led by GT-04686.Key clinical signals include reductions in CSF glucosylsphingosine (GluSph) after 90 days, decreased CSF DOPA decarboxylase (DDC) in high‑GluSph participants, and durable MDS‑UPDRS scores through Day 150. The novel series is ready for IND‑enabling studies; the Part 1 safety profile supported a nine‑month extension expected to complete in September 2026.

2 weeks ago

#GANX Gain Therapeutics Presents Additional Clinical and Biomarker Data from Phase 1b Clinical Study of GT-02287 and Preclinical Data from Novel Chemical Series at AD/PD 2026

www.stocktitan.net/news/GANX/gain-therapeut...

0 0 0 0

Gain Therapeutics Announces Presentations at AD/PDTM 2026 and Provides U.S. FDA Regulatory Update Gain Therapeutics (NASDAQ: GANX) will present Phase 1b interim data for GT-02287 at AD/PD 2026 on March 18, 2026 and at a poster session March 17-21, 2026 in Copenhagen. The company reported CNS target engagement, pathway biomarker effects and early clinical improvement signals.Gain submitted an IND response to the U.S. FDA in March 2026 and expects a reply in the coming weeks; the company remains on track to start a placebo-controlled Phase 2 trial in 3Q 2026.

3 weeks ago

#GANX Gain Therapeutics Announces Presentations at AD/PDTM 2026 and Provides U.S. FDA Regulatory Update

www.stocktitan.net/news/GANX/gain-therapeut...

0 0 0 0

Gain Therapeutics Announces Announces Conference Participation During J.P. Morgan Healthcare Conference Week Gain Therapeutics (NASDAQ: GANX) announced its participation in events during the week of the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, Jan 11–14, 2026.Planned events include: the 9th Annual Sachs Neuroscience Innovation Forum on Jan 11, 2026 (presentation and one-on-ones; presentation at 2:40 p.m., Track C — Rosenberg Room, Marine's Memorial Club), the Demy-Colton/Informa Biotech Showcase on Jan 12–14, 2026 (presentation and one-on-ones; Hilton San Francisco Union Square), and the LifeSci Advisors 15th Annual Corporate Access Event on Jan 14, 2026 (one-on-one meetings; The Beacon Grand).Investors can request in-person meetings via the Biotech Showcase partnering system or by registering/contacting LifeSci Advisors representative Alex Grossman (alex@lifesciadvisors.com).

2 months ago

#GANX Gain Therapeutics Announces Announces Conference Participation During J.P. Morgan Healthcare Conference Week

www.stocktitan.net/news/GANX/gain-therapeut...

0 0 0 0

Gain Therapeutics Highlights Biomarker Evidence Supporting Disease-Modifying Potential of GT-02287 Gain Therapeutics (Nasdaq: GANX) reported Phase 1b biomarker and clinical data for GT-02287 on January 6, 2026, showing biochemical and clinical signals after 90 days of dosing.Key findings: in participants with elevated baseline cerebrospinal fluid glucosylsphingosine (GluSph), GluSph fell 81% on average after 90 days; as of Nov 30, 2025, 19 patients completed Part 1 (90 days), and 15 evaluable patients showed an average -2.20 point change in the sum of MDS‑UPDRS Part II+III (Part II: -0.6; Part III: -1.6). Four patients were excluded from MDS‑UPDRS analysis (two alpha-synuclein assay negative; two missing ‘off’ state scores). The company describes the GluSph reduction as a first-ever CSF observation after a GCase modulator and says results support continued development and evaluation in the dosing extension.

2 months ago

#GANX Gain Therapeutics Highlights Biomarker Evidence Supporting Disease-Modifying Potential of GT-02287

www.stocktitan.net/news/GANX/gain-therapeut...

0 0 0 0

Trade Alerts, Thursday December 18, 2025 – Crystal Equity Research

3 months ago

Small-cap stocks gapping down in trading, Thu Dec 18th - #OCC #JZXN #VMAR #RVYL #PYXS #HOWL #GANX #EVTV #BDRX #AZI #ATON #PSQH #$NMG - More: crystalequityresearch.com/trade-alerts... - #smallcap

0 0 0 0

Gain Therapeutics Announces Positive Results in Key Exploratory Endpoint from its Phase 1b Clinical Study of GT-02287 in People with Parkinson’s Disease Gain Therapeutics (Nasdaq: GANX) announced Phase 1b data showing first-ever reduction of glucosylsphingosine (GluSph) in cerebrospinal fluid (CSF) after 90 days of dosing with GT-02287, a GCase modulator for Parkinson’s disease. The prespecified exploratory endpoint suggests CNS target engagement and increased GCase activity. The 21-participant study had 19 completers; 15 (79%) entered a nine-month extension expected to finish in September 2026. GT-02287 was generally well tolerated and the DMC recommended continuation. A virtual KOL webinar is scheduled for Jan 6, 2026.

3 months ago

#GANX Gain Therapeutics Announces Positive Results in Key Exploratory Endpoint from its Phase 1b Clinical Study of GT-02287 in People with Parkinson’s Disease

www.stocktitan.net/news/GANX/gain-therapeut...

0 0 0 0

Gain Therapeutics Presents Preclinical GT-02287 Data at Neuroscience 2025 GT-02287 reduces mitochondrial stress and enhances neuronal survival in MPP+ treated rat dopaminergic neurons GT-02287 decreases staining for MIRO1, suggesting improved mitochondrial health in α-synuclein-induced mouse PD model GT-02287 improves mitochondrial function by facilitating GCase

4 months ago

#GANX Gain Therapeutics Presents Preclinical GT-02287 Data at Neuroscience 2025

www.stocktitan.net/news/GANX/gain-therapeut...

0 0 0 0

Leading Indicators, Tuesday November 11, 2025 – Crystal Equity Research

4 months ago

Small-cap stocks with improving money flow, Tue Nov 11th - #STAA #ORMP #ADSE #BCIC #CECO #DSGN #EWTX #GANX #HCAI #INNV #PUBM #NTHI #YEXT #VAN #SFL #NVRI #KOP #FIGS #DV #BAK - More: crystalequityresearch.com/leading-indi... - #smallcap

0 0 0 0

Phase 1b Parkinson's Trial Extended: Gain Therapeutics' GT-02287 Shows Encouraging Early Safety Data Biotech firm extends GT-02287 Phase 1b trial by 9 months with 21 enrolled Parkinson's patients. Early safety and efficacy data to be presented at MDS Congress in October 2025.

6 months ago

#GANX Gain Therapeutics Begins Its GT-02287 Phase 1b Extension Study in People with Parkinson’s Disease

www.stocktitan.net/news/GANX/gain-therapeut...

0 0 0 0

12-Month Extension Approved: Gain Therapeutics' Parkinson's Drug Trial Shows Promise in Safety Review Biotech firm receives Australian approval to extend GT-02287 Phase 1b trial from 3 to 12 months. Independent DMC confirms safety profile, majority of participants opt for extension.

6 months ago

#GANX Gain Therapeutics Receives Australian Approval of Phase 1b Dosing Extension and Reports Positive Independent Data Monitoring Committee Recommendation

www.stocktitan.net/news/GANX/gain-therapeut...

0 0 0 0

Market Wire News

@marketwirenews.com

7 months ago

NEWS: ( NASDAQ: #GANX ) Expected earnings - Gain Therapeutics Inc.

0 0 0 0

Gain Therapeutics Fast-Tracks Parkinson's Drug Trial: Key Results Coming Q4 2025, Raises $7.1M Phase 1b Parkinson's study hits enrollment target ahead of schedule. Q4 biomarker data incoming. Fresh $7.1M funding extends runway. Get full clinical milestones.

7 months ago

#GANX Gain Therapeutics Reports Financial Results for Second Quarter 2025 and Provides Corporate Update

www.stocktitan.net/news/GANX/gain-therapeut...

0 0 0 0

Gain Therapeutics Announces Pricing of $7.0 Million Public Offering Gain Therapeutics (Nasdaq: GANX), a clinical-stage biotech company, has announced a $7.0 million public offering of common stock and warrants. The offering consists of 4,501,640 shares at an effective price of $1.55 per share and warrants to purchase up to 2,250,820 shares at $1.65 per share.The warrants will be exercisable immediately upon issuance with a five-year expiration term. Newbridge Securities Corporation is serving as the sole book-running manager. The proceeds will fund the development of GT-02287, their lead product candidate for treating neurodegenerative diseases, including GBA1 Parkinson's disease.The offering is expected to close around July 17, 2025, subject to customary conditions.

8 months ago

#GANX Gain Therapeutics Announces Pricing of $7.0 Million Public Offering

www.stocktitan.net/news/GANX/gain-therapeut...

0 0 0 0

Gain Therapeutics Unveils Strategic Public Offering: Funding Next-Gen Parkinson's Treatment Development Clinical-stage biotech announces stock and warrant offering to advance GT-02287, targeting GBA1 Parkinson's disease treatment. See offering details.

8 months ago

#GANX Gain Therapeutics Announces Proposed Public Offering

www.stocktitan.net/news/GANX/gain-therapeut...

0 0 0 0

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

9 months ago

Small-cap stocks gapping down in trading Jul 1st - #CAPS #ARTL #MULN #GANX #DYN #CLRB #EHAB #ECVT #AMC - More: crystalequityresearch.com/SmCpStr/ - #smallcap

0 0 0 0

Gain Therapeutics' Chief Medical Officer Set to Reveal Latest GBA1 Therapeutic Developments in Montreal Gain Therapeutics' CMO Dr. Hannestad to share new insights on allosteric small molecule therapies at prestigious GBA1 Meeting. Learn about latest developments.

10 months ago

#GANX Gain Therapeutics Announces Oral Presentation at 2nd GBA1 Meeting

www.stocktitan.net/news/GANX/gain-therapeut...

0 0 0 0

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

10 months ago

Small-cap stocks with bearish moving average convergence divergence crossovers, Wed May 14th - #YQ #WBTN #USAU #SAIH #RIGL #PAMT #MBX #KNSA #HCSG #GANX #CGON #AFYA #SVV #HGVC #GETY - More: crystalequityresearch.com/SmCpStr/ - #smallcap

0 0 0 0

Gain Therapeutics' Parkinson's Drug Shows Promise: Key Biomarker Data Coming Mid-2025 GT-02287 Phase 1b trial progresses in Parkinson's patients. Biomarker analysis due mid-2025. Q1 loss improves to $0.16/share. See complete pipeline updates.

10 months ago

#GANX Gain Therapeutics Reports Financial Results for First Quarter 2025 and Provides Corporate Update

www.stocktitan.net/news/GANX/gain-therapeut...

0 0 0 0

Gain Therapeutics Presents Preclinical Data at IAPRD 2025 30th World Congress on Parkinson’s Disease and Related Disorders Gain Therapeutics (NASDAQ: GANX) presented new preclinical data for GT-02287, their clinical-stage therapy for Parkinson's disease, at the IAPRD 30th World Congress. The study demonstrated GT-02287's neuroprotective properties in cultured rat mesencephalic dopaminergic neurons treated with MPP+, a mitochondrial toxin.The research showed that GT-02287 improved both lysosomal and mitochondrial function, while reducing α-synuclein aggregation and preventing the release of mitochondrial cytochrome C, a cell death signal. These findings suggest GT-02287's potential as a disease-modifying therapy through its allosteric modulation of GCase and broader neuroprotective effects.

10 months ago

#GANX Gain Therapeutics Presents Preclinical Data at IAPRD 2025 30th World Congress on Parkinson’s Disease and Related Disorders

www.stocktitan.net/news/GANX/gain-therapeut...

0 0 0 0

Gain Therapeutics Announces Oral Poster Presentation at IAPRD 2025 30th World Congress on Parkinson’s Disease and Related Disorders Gain Therapeutics (Nasdaq: GANX) has announced an upcoming oral poster presentation at the IAPRD 30th World Congress on Parkinson's Disease and Related Disorders. The event will take place from May 7th-10th in New York City. The presentation will focus on GT-02287, the company's clinical-stage allosteric GCase modulator designed for treating Parkinson's Disease. Dr. Joanne Taylor, Senior Vice President of Research at Gain Therapeutics, will present findings demonstrating how GT-02287 protects dopaminergic neurons against mitochondrial toxin MPP+. The presentation is scheduled for Saturday, May 10, 2025, during the Guided Poster Tour session from 8:00-9:00 a.m. EST. This showcase highlights Gain's progress in developing next-generation allosteric small molecule therapies.

11 months ago

#GANX Gain Therapeutics Announces Oral Poster Presentation at IAPRD 2025 30th World Congress on Parkinson’s Disease and Related Disorders

www.stocktitan.net/news/GANX/gain-therapeut...

0 0 0 0

Breakthrough: New Parkinson's Drug Shows Lasting Effects Even After Treatment Stops New preclinical data reveals GT-02287's disease-modifying potential in Parkinson's, with sustained benefits post-treatment. Phase 1b biomarker results expected Q2 2025.

11 months ago

#GANX Gain Therapeutics Presents Additional Preclinical Data and Design of Phase 1b Clinical Study of GT-02287 at AD/PD 2025 and Provides Enrollment Update

www.stocktitan.net/news/GANX/gain-therapeut...

0 0 0 0

New Clinical Trial Details: Gain's Innovative Parkinson's Treatment Heads to Major Conference Latest Phase 1b trial design for GT-02287, targeting GCase in Parkinson's disease, to be unveiled at prestigious AD/PD conference. Full analysis inside.

1 year ago

#GANX Gain Therapeutics Announces Poster Presentation at AD/PD 2025

www.stocktitan.net/news/GANX/gain-therapeut...

0 0 0 0

Breakthrough: Gain Therapeutics' Parkinson's Treatment Achieves 50% Activity Increase in Clinical Trial Phase 1b trial reveals promising efficacy for GT-02287 Parkinson's treatment. Company reduces annual losses while advancing clinical pipeline. Full analysis inside.

1 year ago

#GANX Gain Therapeutics Reports Financial Results for the Fourth Quarter and Year End 2024 and Provides Corporate Update

www.stocktitan.net/news/GANX/gain-therapeut...

0 0 0 0

Promising Parkinson's Treatment Enters Next Phase: Gain's GT-02287 Shows 50% Target Engagement Following successful Phase 1 results with 50% GCase increase, GT-02287 begins testing in Parkinson's patients. Interim analysis expected Q2 2025 for this promising treatment.

1 year ago

#GANX Gain Therapeutics Doses First Participant in Phase 1b Clinical Trial of GT-02287 in Parkinson's Disease

www.stocktitan.net/news/GANX/gain-therapeut...

0 0 0 0

Promising Parkinson's Treatment Advances: Gain Therapeutics Hits Key Clinical Milestone After 50% Target Success Following successful Phase 1 results showing 50% GCase increase, GT-02287 advances to treat GBA1 and idiopathic Parkinson's patients in multi-center Phase 1b study.

1 year ago

#GANX Gain Therapeutics Doses First Participant in Phase 1b Clinical Trial of GT-02287 in Parkinson’s Disease

www.stocktitan.net/news/GANX/gain-therapeut...

0 0 0 0

Can This New Drug Candidate Transform Parkinson's Disease Treatment? Key Data Coming GT-02287 shows promising disease-modifying potential for both GBA1 and idiopathic Parkinson's Disease. Key clinical data to be presented at prestigious AD/PD conference.

1 year ago

#GANX Gain Therapeutics Announces Oral Presentation at AD/PD 2025

www.stocktitan.net/news/GANX/gain-therapeut...

0 0 0 0

Parkinson's Breakthrough: New Drug Shows 53% Enzyme Boost, Phase 1b Trial Launching Gain Therapeutics prepares Phase 1b trial for promising Parkinson's treatment GT-02287 after achieving 53% GCase activity increase. FDA meeting success paves way for 2025 clinical milestones.

1 year ago

#GANX Gain Therapeutics CEO Gene Mack Issues Letter To Shareholders and Provides Operational Update

www.stocktitan.net/news/GANX/gain-therapeut...

0 0 0 0

Gain Therapeutics Advances Parkinson's Treatment: Phase 1b Trial Approved After Promising Early Results Following successful Phase 1 results showing 50% increase in GCase activity, Gain Therapeutics advances GT-02287 to Phase 1b trial for Parkinson's disease treatment in Australia.

1 year ago

#GANX Gain Therapeutics Initiates Phase 1b Clinical Trial of Lead Candidate GT-02287 in People with GBA1 and Idiopathic Parkinson’s Disease

www.stocktitan.net/news/GANX/gain-therapeut...

1 0 0 0